Voice biomarkers as game-changer in improving patient outcomes and reducing costs.
How our SaaS Platform for Voice Analysis works
We provide AI-driven technology to extract digital biomarkers from voice samples.
Created in Germany
ISO-certified infrastructure
Following ISO 13485
Why choose our Voice Biomarker Technology?
Reliability & Accuracy
80%+ accuracy evaluated in ongoing clinical trials
High Accessibility
Voice data easily collected with smartphones
Scalability
Across languages, markets and indications
Non-invasive and cost-effective
Monitoring instrument
Data Protection
Anonymization, encryption and secure storage of patient data
Regulatory Independence
Designed to adapt across country-specific regulations
Would you like to take a look at our latest news?
Read now
Currently, we focus on two applications in respiratory diseases and cardiology — the leading causes of hospitalization worldwide.
Vocal Biomarkers in Heart Failure
- Heart failure fluid retention affects voice and breathing patterns.
- Biomarker detection supports early risk stratification and follow-up.
- Validated datasets collected in clinical studies.
- Patient companion app developed by Zana with participants.
Vocal Biomarkers in Respiratory Diseases
- Voice changes are linked with deterioration and exacerbation risk in COPD.
- Biomarker extraction enables prediction of shortness of breath and declining lung function.
- Validated datasets collected in clinical studies.
- Customized patient companion app for real-world data collection developed by Zana.
Our goal is to democratize the digital biomarkers market
The Zana AI platform is designed to integrate biomarkers and speech analysis tools developed by other industry players, growing into a go-to place for digital biomarker services across various indications.